Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223125 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
A Phase 1 study of Advanced-stage Solid Tumors, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 360
- Enrollment target
- 5
- Study locations
NCT07223125 is a Phase 1 study of Advanced-stage Solid Tumors that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 360 participants. The trial reports 5 study locations across 3 states.
The verdict
NCT07223125, a Phase 1 study of Advanced-stage Solid Tumors, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 360 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
Conditions Studied
Interventions
- DRUG JNJ-89862175
Study Locations (5)
Other
- Centre Leon Berard - Lyon
- Gustave Roussy - Villejuif
- Samsung Medical Center - Seoul
Florida
- AdventHealth Orlando - Orlando
Texas
- NEXT Oncology - Irving
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2025-10-10 |
| Est. Completion | 2028-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223125
The ClinicalTrials.gov registry entry for NCT07223125 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced-stage Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which JNJ-89862175 is the first listed.
NCT07223125 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07223125 about?
NCT07223125 is a clinical study titled "A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors". The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.
What is the current status of trial NCT07223125?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 360 participants. The study started on 2025-10-10. Estimated completion is 2028-08-15.
What conditions does trial NCT07223125 study?
This clinical trial studies the following conditions: Advanced-stage Solid Tumors.
What interventions are being tested in trial NCT07223125?
The interventions under investigation include: JNJ-89862175 (DRUG).
Who is sponsoring clinical trial NCT07223125?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223125 being conducted?
This trial has 5 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.